Guilu Erxian Glue Restores Immune Homeostasis in Aplastic Anemia Mice by Regulating Treg Lineage Stability via the miRNA-17/10a and FasL/Fas Signaling Pathways Authors: Song Sun, Boyang Meng, Jinghao Sang, Wei Liu, Yingkai Zhang, Deze Li, Dongyang Li, Pingxin Zhang, Jingmin Niu, Jie Wei, Limin Chai Published: 2026 ABSTRACT BackgroundThis study investigates the functional role and mechanisms of Guilu Erxian Glue (GEG) in regulating immune homeostasis to treat bone marrow (BM) failure in aplastic anemia (AA).MethodsDifferentially expressed miRNAs of AA patients were identified through bioinformatics analysis of the Gene Expression Omnibus (GEO) database, followed by enrichment analysis of the identified miRNAs and their predicted target genes. The chemical profile of GEG was characterized by UPLC-MS/MS. An AA mouse model was established via 60Co γ-ray irradiation combined with the infusion of an allogeneic lymphocyte suspension for immune induction. GEG + Immunosuppressive therapy (IST) was administered as the therapeutic intervention, with IST + Eltrombopag (EPAG) serving as the positive control. Bone marrow hematopoietic function was evaluated via hematological parameters, BM histopathology, and flow cytometry. CyTOF-2 mass cytometry was utilized to analyze the differentiation profile of CD4+ T-cell subsets, and flow cytometry was further used to detect the proliferation and differentiation of naïve T cells, Tregs, and follicular helper T cells (Tfh). The expression of genes and proteins involved in the miRNA-17/IKZF4, miRNA-10a/BCL6, and Fas pathways was quantified by RT-qPCR and Western blot, with serum cytokines measured by enzyme-linked immunosorbent assay (ELISA).ResultsBioinformatic analysis of the GSE82095 dataset identified significantly dysregulated miRNAs in T cells from AA patients, specifically miRNA-17-5p and miRNA-10a-5p. Preliminary enrichment analysis indicated that these miRNAs are primarily involved in hypoxic stress, T-cell differentiation, and apoptosis. Subsequently, the downstream target genes of these miRNAs were predicted, and further functional enrichment analysis corroborated that these target genes are critically associated with T-cell differentiation. HPLC-MS/MS identified 22 compounds from the aqueous extract of GEG. In vivo, GEG treatment significantly improved BM histopathology and restored peripheral blood counts. It also reduced the percentages of Tfh, Th1, Th17, and effector memory T cells (Tem) (P < 0.01), while increasing the percentages of Tregs and central memory T cells (Tcm) (P < 0.01). Molecular analysis revealed that GEG upregulated miRNA-10a and downregulated miRNA-17 in Tregs (P < 0.01), leading to increased expression of the Foxp3 cofactor IKZF4 and decreased BCL6 expression (P < 0.01). GEG elevated Foxp3 protein levels and inhibited cleaved caspase-3 expression in Tregs, and reduced the levels of pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) (P < 0.01),while enhancing the secretion of anti-inflammatory cytokines (IL-10 and IL-35) (P < 0.01).ConclusionOur findings suggest that GEG contributes to Treg lineage stability and survival through the potential modulation of the miRNA-17/IKZF4, miRNA-10a/BCL6, and Fas/FasL signaling axes. These synergistic effects appear to support the remodeling of T-cell homeostasis and restoration of cytokine balance, offering a promising, miRNA-targeted strategy for enhancing AA therapy that warrants further clinical investigation. Introduction Aplastic anemia (AA) is a bone marrow (BM) failure syndrome characterized by BM hypoplasia and pancytopenia, primarily driven by the aberrant activation of T cells.1 Clinical manifestations typically include refractory and symptomatic hemorrhage, anemia, and recurrent infections, which are driven by a profound reduction in all three peripheral blood lineages—including red blood cells (RBCs), white blood cells (WBCs), and platelets (PLTs) —as well as decreased hemoglobin (HGB) levels.2,3 Globally, the incidence of AA is approximately 2 to 7 cases per million inhabitants per year, with a notably higher prevalence in Asia compared to Western countries.4 While Hematopoietic stem cell transplantation (HSCT) remains a definitive curative option,5,6 its application is often constrained by patient age, donor availability, and the risk of graft-versus-host disease.7 Consequently, immunosuppressive therapy (IST), specifically the combination of anti-thymocyte globulin (ATG) and cyclosporine A (CsA), serves as the standard alternative.8 However, the response rate to IST fluctuates between 60% and 70%, with significant risks of relapse or clonal evolution into myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).9,10 Furthermore, slow hematopoietic recovery and the potential for iron overload-induced organ damage remain significant clinical challenges.11–13Recent efforts to enhance IST efficacy, such as the addition of Eltrombopag (EPAG)—an oral thrombopoietin receptor (TPO-R) agonist—have shown promise in stimulating hematopoietic stem and progenitor cell proliferation and expanding regulatory T cell (Treg) populations.14,15 Nevertheless, EPAG-related hepatotoxicity and potential biliary system damage, mediated through the cytochrome P450 (CYP) enzyme system, necessitate the exploration of safer complementary strategies.16 The central mechanism of AA involves a profound disruption of systemic immunity and the failure of immune tolerance. This process is primarily attributed to both quantitative and functional deficiencies Tregs, which, in a healthy state, maintain homeostasis by suppressing excessive autoimmune responses.17 However, in the inflammatory milieu of AA, Tregs exhibit significant lineage instability and tend to undergo a phenotypic plastic shift toward a follicular helper T cells (Tfh)-like profile. This aberrant conversion not only contributes directly to the contraction of the functional Treg pool but also triggers the uncontrolled expansion and activation of effector T cells (Teff).These activated CD4+ T cells orchestrate a coordinated immune onslaught against the hematopoietic system by secreting high concentrations of pro-inflammatory cytokines, specifically interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α).18,19 These cytokines trigger a cascade that activates the Fas/FasL (CD95/CD178)-mediated apoptotic signaling pathway.20,21 This pathological axis not only results in the direct depletion of hematopoietic stem cells (HSCs) but also compromises the viability of the Treg cell population itself, creating a self-perpetuating cycle of immune-mediated BM failure. The biological functions and lineage stability of Tregs are strictly governed by the master transcription factor Foxp3. Beyond this central orchestrator, these processes are further refined by a sophisticated regulatory network involving epigenetic modifications and non-coding RNAs.22–24 Our group, through Gene Expression Omnibus (GEO) data mining, found that the expression levels of miRNA-10a, and miRNA-17 differ significantly in T cells in BM of AA patients compared to healthy controls. Modulating these miRNAs to restore immunosuppressive function of Tregs may thus represent a promising therapeutic target and a complementary immunomodulatory strategy for AA. Guilu Erxian Glue (GEG), a classical traditional Chinese medicine formula composed of Deer-horn glue (Cervi Cornus Colla), Tortoise-shell glue (Testudinis Carapacis ET Plastri Colla), Ginseng (Ginseng Radix et Rhizoma), and Lycium Barbarum L. (Lycii Fructus), documented in “Yi Bian” is renowned for its “Yin-nourishing and Qi-tonifying” properties and is widely used for hematological disorders.25 Our previous studies have demonstrated that a modified version of the GEG formula can reduce immune-mediated HSC damage.26 Building upon this, the present study provides a detailed investigation into whether GEG preserves Treg lineage stability and prevents apoptotic depletion by modulating the miRNA-17 and miRNA-10a signaling axes, offering a novel miRNA-targeted strategy for AA therapy. Materials and Methods Identification of Differentially Expressed miRNAs in T Cells from AA Patients To identify differentially expressed miRNAs in T cells of AA patients, we searched the GEO database (https://www.ncbi.nlm.nih.gov/geo/) using the keyword “aplastic anemia”. We retrieved the miRNA expression profiling dataset GSE82095, which includes T cell samples from both AA patients and healthy controls. Data analysis was conducted using R software (version 4.5.1). Differential expression analysis was performed by setting thresholds of fold change (logFC)| > 1 and adjusted P-value < 0.05. Significantly differentially expressed miRNAs were visualized using heatmaps and volcano plots to highlight patterns of upregulation and downregulation. Functional Enrichment Analysis of miRNA The predicted miRNA were subjected to functional enrichment analysis using the DIANA-miRPath platform (http://diana.imis.athena-innovation.gr/). Gene Ontology (GO) analysis was performed across three domains: Molecular Function (MF), Biological Process (BP), and Cellular Component (CC). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was also conducted. These analyses aimed to elucidate the potential biological functions and signaling pathways regulated by the differentially expressed miRNAs in the context of AA. Prediction and Enrichment Analysis of miRNA Target Genes Three mature miRNAs, identified as key regulators of Tregs, were selected for downstream target gene prediction. To enhance reliability, we utilized four miRNA-target prediction databases: miRDB (www.mirdb.org), miRTarBase (www.mirtarbase.mbc.nctu.edu)., miRWalk (www.mirwalk.umm.uni-heidelberg.de), and TargetScan (www.targetscan.org). High-confidence target genes were defined by the intersection of predictions from these databases. A miRNA–mRNA regulatory network was constructed using Cytoscape software (version 3.7.2) to visually represent the regulatory relationships.To determine the biological functions and potential signaling pathways of overlapping target mRNAs, GO and KEGG pathway enrichment analyses were performed using the Metascape database (www.metascape.org). Preparation of the GEG Herbal Combination The GEG formula consists of the following four Chinese medicinal herbs: Cervi Cornus Colla (21010203) 10 g, Testudinis Carapacis ET Plastri Colla (20231130) 10 g, Ginseng Radix et Rhizoma (2307080) 10 g, and Lycii Fructus (20231130) 20 g. The plant names and taxonomic nomenclature have been validated in the World Flora Online (www.worldfloraonline.org) and Pharmacopoeia of the People’s Republic of China (www.ydz.chp.org.cn). Except for the two gelatins, the herbal components were macerated in 8 volumes (v/w) of deionized water for 0.5 h. The mixture was initially brought to a boil under high heat and then simmered for 0.5 h. After collecting the first filtrate, the residues were re-decocted with 6 volumes of deionized water for another 0.5 h. During this second decoction, Cervi Cornus Colla and Testudinis Carapacis ET Plastri Colla were added to the boiling liquid for melting and integration. Both extracts were subsequently pooled, filtered, and evaporated to reach a final concentration of 1 g/mL (crude drug equivalent).27,28 Detection by Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) GEG extract was filtered through a 150 μm standard test sieve and freeze-dried using a vacuum freeze dryer (Beijing Boyikang, FD-1A-80, BeiJing) to obtain a powder (Storage at −80 °C). The powder extraction yield of GEG was approximately 57 ± 1.2% (w/w). The freeze-dried powder was dissolved in methanol/water (1:1, v/v), then centrifuged at 13,000 rpm for 15 minutes, filtered through a 0.22 μm filter membrane and transferred to an injection vial. The supernatant was analyzed using an SCIEX ExionLC AD UPLC system coupled with an SCIEX X500R Q-TOF mass spectrometer (equipped with an ESI electrospray ionization source). Separation used a Waters ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm) with a mobile phase of 0.05% formic acid in water (A) and acetonitrile (B), at 0.3 mL/min. MS acquisition employed information-dependent acquisition (IDA) in positive and negative modes. Key settings were: ion spray voltage: ±5500 V; source temperature: 500 °C; gas pressures (nebulizer: 50, auxiliary: 60, curtain: 30 psi); scan ranges: m/z 100–2000 Da (TOF-MS) and m/z 50–2000 Da (TOF-MS/MS).All chemical profiling experiments were performed in triplicate. Mouse Rearing and Induction of AA Model In accordance with the 3R (Replacement, Reduction, Refinement) principles for animal research, a pilot experiment was conducted prior to the formal study. The animal model of AA and the therapeutic effects of each drug regimen were preliminarily assessed using complete blood count (CBC) analysis and hematoxylin and eosin (HE) staining.For the pilot experiment, female BALB/c mice (6 mice per group, 7–8 weeks old) and one female DBA/2 mouse (10 weeks old) were used. In the formal study, female BALB/c mice (14 mice per group, 7–8 weeks old) and two female DBA/2 mice (10 weeks old) were employed. All animals were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. (Animal Production License No.: SCXK (Beijing) 2021–0011). This study was approved by the Animal Ethics Committee of Dongzhimen Hospital, Beijing University of Chinese Medicine, and all procedures adhered to the guidelines and regulations set by the Animal Ethics Committee of Dongzhimen Hospital, Beijing University of Chinese Medicine (Animal ethics batch number: No. 22–24), (Laboratory Animal Usage License: No. SYXK (Beijing) 2020–0013). According to the guidelines of the American Veterinary Association (https://www.avma.org/resources-tools/avma-policies/avma-guidelines-euthanasia-animals), mice were deeply anesthetized by intraperitoneal injection of 1% pentobarbital sodium (50 mg/kg). The depth of anesthesia was confirmed by the absence of pedal and tail-pinch reflexes. Blood was then collected from the retro-orbital venous plexus. Immediately thereafter, while still under deep anesthesia, the mice were euthanized by an intraperitoneal overdose of 5% pentobarbital sodium (200 mg/kg). Death was confirmed by cessation of breathing followed by bilateral thoracotomy. Post-mortem tissue collection was then performed. After euthanasia of DBA/2 mice, thymus and lymph nodes were collected to prepare single-cell suspensions. Cell viability was assessed using Trypan Blue staining (> 95%). Mice were irradiated with a sublethal dose of 3.5 Gy using a 60Co γ-ray source, followed by the injection of thymus and lymph node cell suspensions (1 × 106 cells, 0.2 mL per mouse) in the tail vein within 4 h. All mice, except those in the normal control group, were randomly assigned to four groups and administered treatment 1 day after irradiation. Drug Treatment and Grouping All mice, except those in the model group, received 28 days of treatment. In the pilot study, mice were randomly divided into six groups. The normal group was given standard feeding. The model group received the same diet as the normal group but was administered sterile saline via oral gavage. The dose for mice was estimated using the Body Surface Area (BSA) normalization method based on the clinical dosage for AA patients, according to the dose exchange algorithm.29 According to the body surface area measurement algorithm, the daily use of GEG by an adult weighing 60kg is converted to 10g/kg/d for Chinese herbal decoction to mice. The IST group received the same diet as the control group and was treated with tail vein injections of ATG (Genzyme Polyclonals S.A.S, J20150136, USA)(0.12 mg/day) for 5 consecutive days, followed by continuous oral gavage of CsA (Hangzhou Sino American Huadong Pharmaceutical Co., Ltd, H10960122, China) (0.03 mg/day) for 28 days. The IST combined with EPAG (Novartis Pharma Schweiz AG, H20170387, Switzerland) group (IST + EPAG) received the normal diet and, in addition to IST treatment, was administered EPAG (0.45 mg/day) for 28 consecutive days. The IST combined with the clinically equivalent dose of GEG group (IST + CEDGEG) received the normal diet and, in addition to IST treatment, was given GEG decoction (0.2g/day) for 28 consecutive days. The IST combined with high-dose GEG group (IST + HDGEG) received GEG decoction (0.6 g/day) for 28 days in addition to IST treatment. The usage of GEG is based on previous research.30 This experiment focuses on clinical equivalent doses and provides effect anchoring through positive controls (IST + EPAG), which can meet the needs of mechanism exploration. Before the formal experiment, we treated mice with different doses of traditional Chinese medicine compound drugs and observed the number of hematopoietic stem cells and BM apoptosis in mice by HE staining and flow cytometry. We found that the equivalent dose drug had the most significant therapeutic effect.In accordance with the 3R principles, the equivalent dose of GEG was selected for treatment in the formal experiment. Complete Blood Cell Analysis Complete blood cell analysis was performed on mice at baseline Day 0, Day 7, Day 14, and Day 28 following drug intervention. A 10 μL blood sample was collected from the tail tip of each mouse and analyzed using a hematology analyzer (Nihon Kohden, DXH 900, Tokyo, Japan). The levels of RBCs, WBCs, HGB, and PLTs were quantified. Hematoxylin and Eosin (HE) Staining After 28 days of treatment, the femur from one side of 3 mice from each group was collected, fixed overnight in 4% paraformaldehyde (Mindray, D022, Shenzhen, China), and then decalcified in 10% Ethylenediaminetetraacetic acid (EDTA) solution (Solarbio, P1110, Beijing, China) for 14 days. After decalcification, the bone tissue was embedded in paraffin according to standard protocols. Tissue sections were deparaffinized using xylene and subsequently rehydrated through a graded ethanol series. Finally, the sections were stained using the HE staining method. Pathological changes in the tissues were observed and photographed under an optical microscope (Leica, DM RAS2, Germany). Flow Cytometry Analysis Single-cell suspensions were prepared by filtering Bone Marrow Cells (BMCs) flushed from the femoral cavity and mechanically dissociated splenocytes through a 200-mesh strainer. For HSCs quantification, BMCs were stained with anti-mouse CD117-PE antibody and CD45-APC antibody (BD Bioscience, 561075, 561018, USA), while BMC apoptosis was assessed using an Annexin V-FITC/PI Apoptosis Detection Kit (BOSTER, MK1028, China). Splenic T cell subsets were analyzed using specific antibody panels: Tregs were identified by staining with anti-mouse CD4-FITC, CD25-PE (BioLegend, 100406, 102008, USA), and Foxp3-APC (Invitrogen, 17–5773-82, USA); effector T cells were detected using anti-mouse CD4-FITC, CD44-PE, and CD62L-APC (BioLegend, 100406, 103,024, 104411, USA); and Tfh cells were labeled with anti-mouse CD4-FITC, CD185-PE, and CD278-APC (BioLegend, 107712, 145,504, 145504, USA). Flow cytometry was performed on a Cytomics FC 500 system (Beckman Coulter, Cytomics FC 500, USA), and data were analyzed using CytExpert software (Version 2.5). CyTOF-2 Mass Cytometry Analysis Peripheral blood mononuclear cells (PBMCs) were isolated from mouse peripheral blood using a mouse peripheral blood mononuclear cell isolation kit (solarbio, P6340, Beijing, China). The isolated cells were incubated with a 2 μM cisplatin working solution (Invitrogen, 00–4975-93, USA) for 4 hours, followed by fixation with 1.6% paraformaldehyde. Subsequently, cells were labeled using the Maxpar® X8 Antibody Labeling Kit to conjugate surface antibodies with metal tags. Cells were first labeled with a pre-mixed cocktail of metal-conjugated surface antibodies and incubated at 4°C for 30 minutes. Following fixation and permeabilization, an intracellular antibody cocktail was introduced for cell labeling, with incubation at room temperature for 30 minutes. Finally, cells were resuspended in 10% EQ™ Four Element Calibration Beads and thoroughly mixed. All data were analyzed using the X-shift clustering algorithm and non-linear dimensionality reduction via t-Distributed Stochastic Neighbor Embedding (t-SNE). Data visualization was performed using the Visual Stochastic Network Embedding (viSNE) method. CD4+ T cells subsets were defined as follows: Th1 cells (CD4+IFN-γ+T-bet+), Th2 cells (CD4+IL-4+GATA3+), Th17 cells (CD4+ IL-17+ RORγT+), Tregs (CD4+CD25+Foxp3+). Real-Time Quantitative PCR Detection Total RNA was extracted from CD4+ T cells isolated from the spleen using magnetic bead sorting,strictly adhering to the manufacturer’s protocol (Miltenyi, 130–117-043, Germany), and flow cytometry was used to verify the purity of the sorted CD4+ T cells.Total RNA and miRNA were isolated from CD4+ T cells using the MagZol assay kit (Magen, R4310-02, China), followed by concentration evaluation using NanoDrop 2000 (Thermo Scientific, USA).The cDNA was synthesized via reverse transcription using the miRNA tailing method using a miRNA 1st Strand cDNA Synthesis Kit (Vazyme, MR201-02, China). Using HiScript ® III All in one RT SuperMix Perfect for qPCR (Vazyme, R333-01, China) reverse transcribes RNA samples into cDNA.Subsequently, concentration evaluation was conducted using NanoDrop 2000 (Thermo Scientific, USA). Real-time quantitative PCR was performed using the Taq Pro Universal SYBR qPCR Master Mix (Vazyme, Q712-02, China) to detect the expression of the target miRNA-17 and miRNA-10a, with U6 snRNA used as the internal control. For the target mRNA (IKZF4, HIF1α, and BCL6), specific primers were designed, and SYBR Green-based real-time quantitative PCR was employed to assess their expression. GAPDH was used as the internal control for mRNA quantification. Primer design for RNA is shown in Table 1. The relative expression levels of the target miRNA and mRNA were calculated using the 2−ΔΔCt method.Table 1Primers Used for Quantitative Real-Time PCRNamePrimer SequencemiRNA-17-5pForward:5′-CCGACTGCAGTGAGGGCACTTGTAG-3′miRNA-10a-5pForward:5′-CGCCGGTGAGAACTGAATTCCATGGG-3′U6Forward:5′-CTCGCTTCGGCAGCACA-3′Reverse:5′-AACGCTTCACGAATTTGCGT-3′mRNA-HIF1αForward:5′-GGGCACCGATTCGCCAT-3′Reverse:5′-TCGACGTTCAGAACTCATCCT-3′mRNA-BCL6Forward:5′-GAAAGGCCGGACACCAGTTT-3′Reverse:5′-GGAGGCCATGTTGTGTTTGC-3′mRNA-IKZF4Forward:5′-CTTTATTTTGTGAAAGCCTTTGCG-3′Reverse:5′-GAGTCCCCGCTACCTACTGG-3′GAPDHForward:5′-AGGTCGGTGTGAACGGATTTG-3′Reverse:5′-GGGGTCGTTGATGGCAACA-3′ Table 1Primers Used for Quantitative Real-Time PCRNamePrimer SequencemiRNA-17-5pForward:5′-CCGACTGCAGTGAGGGCACTTGTAG-3′miRNA-10a-5pForward:5′-CGCCGGTGAGAACTGAATTCCATGGG-3′U6Forward:5′-CTCGCTTCGGCAGCACA-3′Reverse:5′-AACGCTTCACGAATTTGCGT-3′mRNA-HIF1αForward:5′-GGGCACCGATTCGCCAT-3′Reverse:5′-TCGACGTTCAGAACTCATCCT-3′mRNA-BCL6Forward:5′-GAAAGGCCGGACACCAGTTT-3′Reverse:5′-GGAGGCCATGTTGTGTTTGC-3′mRNA-IKZF4Forward:5′-CTTTATTTTGTGAAAGCCTTTGCG-3′Reverse:5′-GAGTCCCCGCTACCTACTGG-3′GAPDHForward:5′-AGGTCGGTGTGAACGGATTTG-3′Reverse:5′-GGGGTCGTTGATGGCAACA-3′ Primers Used for Quantitative Real-Time PCR Enzyme-Linked Immunosorbent Assay (ELISA) After the final dose administration, 0.8 mL of blood was collected from the retroorbital venous plexus of each mouse. The blood was centrifuged at 3000 rpm for 10 minutes at 4°C to separate the serum. The serum levels of FasL, IFN-γ, TNF-α, IL-6, IL-10, IL-35, IL-4, IL-17 (Elabscience, E-EL-M0028c, E-EL-M0048c, E-EL-M3063, E-EL-M0044, E-EL-M0046, E-EL-M0733, E-EL-M0043, E-EL-M0006, USA) and TGF-β1 (Invitrogen, BMS608-4, USA) were measured using ELISA kits according to the manufacturer’s instructions. Western Blot Analysis Spleens were harvested and mechanically dissociated, followed by flushing with cold phosphate-buffered saline (PBS)(Solarbio, P1020, Beijing, China) to generate a single-cell suspension. CD4+ T lymphocytes were then purified from the splenocytes using magnetic-activated cell sorting (MACS), strictly according to the manufacturer’s instructions (Miltenyi Biotec, 130–117-043, Germany).CD4+ T lymphocytes were collected in RIPA buffer (Sigma, St. Louis, MO, USA). Following protein quantification using the BCA method, samples were separated by 10% SDS-PAGE gel electrophoresis and transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). The membranes were incubated with primary antibodies Fas (R&D, AF435, USA), caspase-7, cleaved caspase-7 (Cell Signaling Technology, CST9492, CST9491, USA), Caspase-8 (R&D, AF705, USA), Cleaved Caspase-8 (Cell Signaling Technology, CST8592, USA), and GAPDH (Proteintech, hp-60004, USA). Tregs underwent purification using MACS (Miltenyi, 130–091-041, Germany). Protein extraction and quantification are the same as above.The membranes were incubated with primary antibodies Caspase-3, Cleaved Caspase-3 (Novus, NB100-56708, USA), with GAPDH (Proteintech, hp-60004, USA).Subsequently, the membranes were incubated for 1h with HRP-conjugated secondary antibodies and subjected to chemiluminescent detection using ECL reagent (NCM Biotech, P10100, Suzhou, China). GAPDH was used as the internal control, and all optical density measurements were normalized to it. Each experiment was repeated three times, and protein expression densities were quantified using ImageJ software (Bethesda, USA). WES Automated Protein Blotting Analysis Tregs underwent purification using MACS (Miltenyi, 130–091-041, Germany). Due to the small number of Tregs in the sorted sample and the low abundance of related proteins, we chose the highly sensitive WES fully automatic protein quantification detector (Protein Simple, America) for protein quantification detection, which is consistent with the traditional Western blot detection principle. The cells were lysed with RIPA buffer. After protein quantification using the BCA method, the appropriate volume of detection antibodies, including HIF-1α (Cell Signaling Technology, CST36169, USA), IKZF4 (Abcam, ab220329, USA), Foxp3 (BOSTER, MA00011, China), BCL6 (R&D, AF5046, USA) and GAPDH (Proteintech, hp-60004, USA), were added to the wells and incubated as per the kit’s instructions. The fluorescence reference, Ladder, and samples were examined using Compass software (Version 6.2.0) to ensure no abnormalities before proceeding with data analysis and image export. Each experiment was repeated three times, with GAPDH used as the reference gene. Statistical Analysis All data are presented as the mean ± standard deviation (S.D). Statistical analysis was performed using SPSS 20.0 software (SPSS Inc, Chicago, IL, USA). Differences between treatment groups were compared using one-way analysis of variance (ANOVA) followed by Tukey-Kramer post-hoc test for multiple comparisons. P < 0.05 was considered statistically significant. Results Identification of Differentially Expressed miRNAs in AA Analysis of differentially expressed miRNAs (DEMs) obtained from the GEO database revealed significant alterations in the expression of miRNA-17, miRNA-10a, and miRNA-146a (Figure 1A). The specific expression levels of DEMs in AA and adjacent normal samples is shown in Figure 1B. To further investigate the mechanisms associated with these three miRNAs, we predicted their target genes using the online tools TargetScan and miRDB. GO and KEGG enrichment analyses were subsequently performed using the R package clusterProfiler. The results suggested that miRNA-17, miRNA-10a, and miRNA-146a may be involved in 12 functional pathways (Figure 1C) and 20 signaling pathways (Figure 1D). Enriched biological processes included the cell cycle, HIF-1, TNF, and TGF-β signaling pathways (Figure 1C), while signaling pathways such as T cell differentiation and apoptosis were also significantly identified (Figure 1D). Figure 1Identification of differentially expressed microRNAs (DEMs) associated with aplastic anemia (AA). (A) Volcano plots of DEMs. (B) Heatmap of DEMs in both AA and healthy control samples. (C) GO enrichment analysis. Red boxes highlight four core pathways (FoxO, HIF-1, TNF, and TGF-β) closely associated with Treg homeostasis and dysfunction. (D) KEGG pathway analysis.Image A is a volcano plot of microRNAs, with log2(FoldChange) on the x-axis (-3 to 2) and -log10(p-value) on the y-axis (0 to 6). Thresholds are at log2(FoldChange) of -0.5 and 0.5 and -log10(p-value) of 1. Notable points include hsa-miR-10a (-1.6, 3.2), hsa-miR-146a (-2.2, 0.6) and hsa-miR-17 (1.2, 2.5), with more points on the negative side. Image B is a heatmap with a dendrogram comparing Aplastic anemia and Normal groups, showing lower values with a high-value band at the top. Image C is a bubble plot for GO enrichment analysis, with genes (30-80) on the x-axis and terms like PI3K–Akt and MAPK pathways on the y-axis. PI3K–Akt has ~78 genes, MAPK ~62. Image D is a KEGG Pathway bubble plot, with x-axis ticks at 0, 200, 400, 600 and terms like Signal transduction and Response to stress. Signal transduction has the highest gene count near 600. The plots highlight specific microRNAs, expression patterns and enriched terms.A composite figure with a volcano plot, a heatmap and two bubble plots of pathway enrichment. Identification of differentially expressed microRNAs (DEMs) associated with aplastic anemia (AA). (A) Volcano plots of DEMs. (B) Heatmap of DEMs in both AA and healthy control samples. (C) GO enrichment analysis. Red boxes highlight four core pathways (FoxO, HIF-1, TNF, and TGF-β) closely associated with Treg homeostasis and dysfunction. (D) KEGG pathway analysis. Construction of miRNA–mRNA Network and Functional Enrichment Analysis of Downregulated Target mRNAs It is known that upregulated miRNAs can promote or suppress AA initiation and progression by downregulating target mRNAs. Therefore, we conducted further analyses using the target genes of upregulated miRNA-17 and downregulated miRNA-10a and miRNA-146a. Downstream target mRNAs of these three mature miRNAs were identified using miRDB, miRTarBase, miRWalk, and TargetScan (Figure 2A). To improve prediction accuracy, we selected only potential mRNAs that were associated with AA-related DEGs and were predicted by at least two databases. This approach revealed associations between the miRNAs and 15 corresponding target mRNAs (Figure 2B). GO and KEGG enrichment analyses of these 15 target mRNAs indicated significant enrichment in processes related to hematopoietic regulation and T cell differentiation (Figure 2C and D). Figure 2Prediction of target mRNAs, construction of miRNA-mRNA networks, and functional enrichment analysis. (A) Overlapped target mRNAs were analyzed using the predicted target mRNAs, differentially expressed genes (DEGs) associated with AA, and significantly-differentially expressed mRNAs, respectively. (B) miRNA–mRNA network was constructed using the three miRNAs for AA prognosis and 15 overlapped target mRNAs. (C) GO enrichment analysis. (D) KEGG pathway analysis.The infographic consists of four parts. (A) Venn diagrams show overlapped target mRNAs analyzed using predicted target mRNAs, differentially expressed genes (DEGs) associated with AA and significantly-differentially expressed mRNAs for hsa-mir-10a-5p, hsa-mir-17-5p and hsa-mir-146a-5p. (B) A miRNA-mRNA network diagram illustrates connections between three miRNAs for AA prognosis and 15 overlapped target mRNAs, including PTX3, BCL6, STK3, LTB, NFATC2, IL12RB1, RORA, GATA3, STAT5A, PPARGC1B, CREB1, IKZF2, PRKCB, EIF3F and IKZF1. (C) GO enrichment analysis graph shows significant enrichment in processes like regulation of hematopoiesis and T cell differentiation. (D) KEGG pathway analysis graph highlights pathways such as Th17 cell differentiation, Hepatitis B and non-small cell lung cancer, with q-values and gene ratios indicated.Infographic on miRNA-mRNA networks, target mRNAs, GO and KEGG analysis for AA prognosis. Prediction of target mRNAs, construction of miRNA-mRNA networks, and functional enrichment analysis. (A) Overlapped target mRNAs were analyzed using the predicted target mRNAs, differentially expressed genes (DEGs) associated with AA, and significantly-differentially expressed mRNAs, respectively. (B) miRNA–mRNA network was constructed using the three miRNAs for AA prognosis and 15 overlapped target mRNAs. (C) GO enrichment analysis. (D) KEGG pathway analysis. Composition of Purified Compounds in the Herbal Formula GEG 22 substances in the GEG water extract freeze-dried powder were identified by UPLC-MS/MS technology, including Amentoflavone (1), Arginine (2), Vitamin C (3), p-Coumaric acid (4), Chlorogenic acid (5), Caffeic acid (6), Tryptophan (7), Rutin (8), Baicalin (9), Ginsenoside Rg1 (10), Ginsenoside Rf (11), Notoginsenoside R2 (12), Ginsenoside-Rg2 (13), Ginsenoside Rh1 (14), Ginsenoside Rb1 (15), Betulin (16), Ginsenoside-Rb2 (17), Ginsenoside-Rb3 (18), Ginsenoside Rd (19), and Ginsenoside F2 (20), Gingerglycolipid B (21), Stigmasterol (22). The Total Ion Chromatogram (TIC)of negative base peaks and positive base peaks were shown in Figure 3A and B. The retention times (tR), molecular formulas, Area and the identification of material components are presented in the Table 2. The Extracted ion chromatograms (XIC) and Tandem mass spectrometry (MS/MS) spectra of the main active constituents with relatively High peak area are presented in Figure 3C.Table 2Chemical Components Identified in GEG by UPLC-MS/MSPeaktR (min)FormulaIdentificationArea10.98C30H18O10Amentoflavone2.51E+0520.82C6H14N4O2Arginine1.15E+0631.00C6H8O6Vitamin C8.91E+0545.66C9H8O3p-Coumaric acid1.09E+0656.98C16H18O9Chlorogenic acid5.01E+0567.07C9H8O4Caffeic acid2.61E+0579.47C11H12N2O2Tryptophan4.21E+05811.4C27H30O16Rutin5.56E+06913.91C21H18O11Baicalin1.40E+061015.93C42H72O14Ginsenoside Rg11.91E+071118.81C42H72O14Ginsenoside Rf4.68E+061219.36C41H70O13Notoginsenoside R22.58E+061319.95C42H72O13Ginsenoside-Rg21.82E+061420.10C36H62O9Ginsenoside Rh12.54E+061522.19C54H92O23Ginsenoside Rb14.52E+061622.85C30H50O2Betulin1.07E+051722.57C53H90O22Ginsenoside-Rb24.03E+061823.12C53H90O22Ginsenoside-Rb32.89E+061924.06C48H82O18Ginsenoside Rd2.13E+062027.15C42H72O13Ginsenoside F21.09E+052127.48C33H58O14Gingerglycolipid B9.91E+042234.76C29H48OStigmasterol1.79E+05 Figure 3The chemical components of GEG identified by HPLC-MS/MS. (A) Positive ion mode mass spectrum. (B) Negative ion mode mass spectrum. (C) Retention time spectra of the water extract of GEG lyophilized powder prepared by UPLC-MS/MS. Secondary mass spectra of Baicalin, Ginsenoside Rb1 and Rutin. X-axis: retention time, Y-axis: chromatographic peak intensity.Image A: Chromatogram (0-38 min, 0.0e0 to 2.0e6 intensity). Peaks: 1, 3 (~2 min); tall peak (~22 min); 16 (~23 min); 17 (~24 min, highest); 20, 21 (~28-29 min); 22 (~35-36 min). Image B: Chromatogram (0-38 min, 0e0 to 7e5 intensity). Tall peak (~1 min). Peaks: 4, 5, 6 (~6-8 min); 7, 8 (~10-12 min); 9 (~14 min); 10 (~16 min); 11, 12, 13 (~18-19 min); 14, 15, 17, 18, 19 (~21-24 min); 20 (~26 min); taller peaks (~30-33 min). Image C: Ion chromatograms and MS plots. Baicalin: Time (13.0-15.0 min), peak at 13.911. Ginsenoside Rb1: Time (21.0-23.5 min), peak at 22.191. Rutin: Time (10.5-12.5 min), peak at 11.402. Baicalin MS: Mass/Charge (100-500 Da), peaks at 59.0140, 223.0397, 269.0448. Ginsenoside Rb1 MS: Mass/Charge (100-1100 Da), peaks at 179.0557, 783.4892, 1107.5923, 1108.5971. Rutin MS: Mass/Charge (100-650 Da), peaks at 151.0037, 301.0345, 307.0261, 609.1437, 610.1511, 617.0247.Three chromatograms and three mass spectra of GEG extract, highlighting major peaks and compounds. Table 2Chemical Components Identified in GEG by UPLC-MS/MSPeaktR (min)FormulaIdentificationArea10.98C30H18O10Amentoflavone2.51E+0520.82C6H14N4O2Arginine1.15E+0631.00C6H8O6Vitamin C8.91E+0545.66C9H8O3p-Coumaric acid1.09E+0656.98C16H18O9Chlorogenic acid5.01E+0567.07C9H8O4Caffeic acid2.61E+0579.47C11H12N2O2Tryptophan4.21E+05811.4C27H30O16Rutin5.56E+06913.91C21H18O11Baicalin1.40E+061015.93C42H72O14Ginsenoside Rg11.91E+071118.81C42H72O14Ginsenoside Rf4.68E+061219.36C41H70O13Notoginsenoside R22.58E+061319.95C42H72O13Ginsenoside-Rg21.82E+061420.10C36H62O9Ginsenoside Rh12.54E+061522.19C54H92O23Ginsenoside Rb14.52E+061622.85C30H50O2Betulin1.07E+051722.57C53H90O22Ginsenoside-Rb24.03E+061823.12C53H90O22Ginsenoside-Rb32.89E+061924.06C48H82O18Ginsenoside Rd2.13E+062027.15C42H72O13Ginsenoside F21.09E+052127.48C33H58O14Gingerglycolipid B9.91E+042234.76C29H48OStigmasterol1.79E+05 Chemical Components Identified in GEG by UPLC-MS/MS The chemical components of GEG identified by HPLC-MS/MS. (A) Positive ion mode mass spectrum. (B) Negative ion mode mass spectrum. (C) Retention time spectra of the water extract of GEG lyophilized powder prepared by UPLC-MS/MS. Secondary mass spectra of Baicalin, Ginsenoside Rb1 and Rutin. X-axis: retention time, Y-axis: chromatographic peak intensity. GEG Ameliorates Hematopoietic Dysfunction and BM Pathology in Mice To evaluate whether GEG could enhance the effects of IST on hematopoietic function in AA mice, peripheral blood parameters—specifically WBCs, RBCs, HGB, and PLTs—were analyzed, as shown in Figure 4A.On Day 0 of drug intervention, the number of WBCs in the peripheral blood of the model group was significantly decreased compared to the normal mice (P < 0.01). Furthermore, on Days 7 and 21 of treatment, the model group mice showed a significant reduction in the numbers of RBCs, HGB, and PLTs compared to the normal mice (P < 0.01). On Day 28 of drug intervention, the number of WBCs, RBCs, HGB and PLTs in the peripheral blood of the each medication group was significantly increased compared to the model group (P < 0.01, P < 0.05). The enhancing effect of CEDGEG on the hematopoietic function of IST restored AA mice is equivalent to IST + EPAG, which is superior to IST alone and IST combined with HDGEG. Figure 4IST + CEDGEG improved peripheral blood hematological parameters and pathological immune injury in AA mice. (A) Peripheral hematological parameters of mice, including WBC, RBC, HGB, and PLT. WBC, white blood cell; RBC, red blood cell; PLT, platelet; HGB, hemoglobin. Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01. (B) HE staining of femoral bone marrow. Scale bar: 40× corresponds to 3000 μm; 200× corresponds to 600 μm.The figure contains multiple graphs and images. Image A includes four line graphs showing hematological parameters over time. The x-axis represents days (0, 7, 14, 28). The y-axis for WBC is labeled as 1 times 10 superscript 9 per liter, for RBC as 1 times 10 superscript 12 per liter, for HGB as grams per liter and for PLT as 1 times 10 superscript 9 per liter. The legend distinguishes groups N, M, IST, IST plus EPAG, IST plus GEG(CED) and IST plus GEG(HD) using different colors and markers. WBC levels in group N remain around 10, while others drop near Day 7 and recover by Day 28. RBC levels are stable across groups, ranging from 4 to 6. HGB levels for N stay near 200, while others show a decline and partial recovery. PLT levels drop sharply at Day 7, with N recovering to around 1500 by Day 28. Image B shows HE staining of femoral bone marrow at 40x and 200x magnifications, highlighting differences in cellularity and hematopoietic cell density across the same groups.Graphs and images reveal blood and marrow changes in AA mice under various treatments. IST + CEDGEG improved peripheral blood hematological parameters and pathological immune injury in AA mice. (A) Peripheral hematological parameters of mice, including WBC, RBC, HGB, and PLT. WBC, white blood cell; RBC, red blood cell; PLT, platelet; HGB, hemoglobin. Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01. (B) HE staining of femoral bone marrow. Scale bar: 40× corresponds to 3000 μm; 200× corresponds to 600 μm. After 28 days of treatment, HE-stained BM tissues were examined. Compared to the normal group, the BM tissues of normal mice were well-filled, with normal development and distribution of hematopoietic cells (Figure 4B). In contrast, in the model group, the BM cavity was largely replaced by adipocytes, and the number of nucleated cells was significantly reduced, with a notable decrease in the proliferation activity of BMCs. Compared to the model group, BM pathological changes of IST + GEG and IST + EPAG group were significantly improved, with a marked increase in nucleated cells and a reduction in adipocyte vacuoles, which the improvement of BM injury was better than using IST alone or IST combined with HDGEG. GEG Promoted HSCs Regeneration and Inhibited the Apoptosis of BMCs Flow cytometry was used to assess the proportion of HSCs in the BM (Figure 5A and B) and the proportion of apoptotic BMCs (Figure 5C and D). Compared to the normal group, the number of HSCs in the model group was significantly decreased (P < 0.05), and the apoptosis rate of BMCs was significantly increased (P < 0.01). However, after treatment, IST + GEG and IST + EPAG groups showed a significant increase in the number of HSCs (P < 0.05) and a marked decrease in the apoptosis rate of BMCs compared to the model group (P < 0.01). The number of hematopoietic stem cells in the IST group significantly increased (P < 0.05), while the apoptosis rate of BMCs showed a decreasing trend but no significant difference. These results indicate that both GEG group and EPAG can enhance the inhibitory effect of IST on BMCs apoptosis, which was superior to IST alone. Figure 5IST + GEG improved hematopoietic function and cell subset differentiation in AA mice. (A) Percentage of CD117+Sca-1+ HSCs in mouse BMCs. (B) Bar chart showing the ratio of HSC numbers. (C) Percentage of V-PI positive cells in mouse BMCs. (D) Bar chart showing the apoptosis ratio of BMCs. (E) Cluster analysis and t-SNE visualization of Th1, Th2, Th17 and Treg cells. (F) Bar chart of CD4+ T cell subsets. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01.A) Five CD117 vs CD45 scatter plots show percentages: N 64.17%, M 49.32%, IST 54.95%, IST+EPAG 55.36%, IST+GEG 55.00%. B) HSCs percentage bar chart: N ~60%, M ~50%, IST ~55%, IST+EPAG ~56%, IST+GEG ~57%. Significance indicated with asterisks. C) Annexin V-FITC vs PI scatter plots show apoptosis percentages: N 7.7%, M 12.3%, IST 10.9%, IST+EPAG 8.4%, IST+GEG 8.2%. D) Apoptosis in BMCs bar chart: N ~8%, M ~12%, IST ~10%, IST+EPAG ~8.5%, IST+GEG ~8.5%. Significance marked. E) t-SNE maps for Treg, Th1, Th2, Th17, Undefined categories show clusters for groups N, M, IST, IST+EPAG, IST+GEG. F) CD4 T cell subsets bar charts: Th1 N 2.5, M 4.0, IST 3.2, IST+EPAG 3.8, IST+GEG 3.3; Th2 N 2.5, M 1.3, IST 1.7, IST+EPAG 1.6, IST+GEG 1.9; Treg N 2.0, M 2.4, IST 2.7, IST+EPAG 3.0, IST+GEG 2.9; Th17 N 3.0, M 3.2, IST 3.1, IST+EPAG 2.8, IST+GEG 2.5. Significance indicated with asterisks.Six-panel plots compare HSCs, apoptosis and CD4 T cell subsets across five mouse groups. IST + GEG improved hematopoietic function and cell subset differentiation in AA mice. (A) Percentage of CD117+Sca-1+ HSCs in mouse BMCs. (B) Bar chart showing the ratio of HSC numbers. (C) Percentage of V-PI positive cells in mouse BMCs. (D) Bar chart showing the apoptosis ratio of BMCs. (E) Cluster analysis and t-SNE visualization of Th1, Th2, Th17 and Treg cells. (F) Bar chart of CD4+ T cell subsets. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01. GEG Restored CD4+ T-Cell Subset Balance We observed alterations in the proportions of CD4+ T cell subsets within PBMCs of mice with AA by CyTOF-2 Mass Cytometry Analysis (Figure 5E and F). Compared to the normal group, the model groups exhibited a significant increase in the proportions of Th1 and Th17 cells, alongside a significant decrease in the proportions of Th2 and Treg cells (P < 0.01, P < 0.05). However, following treatment, each drug treatment groups showed a significant decrease in Th1 and Th17 cell proportions and a significant increase in Th2 and Treg cell proportions compared to the model group (P < 0.01, P < 0.05) (Figure 5F). Overall, IST + GEG and IST + EPAG showed better results in regulating subpopulations of CD4+ T cells compared to using IST alone. GEG Rebalanced the Inflammatory Milieu to Promote Hematopoietic Recovery in AA Mice ELISA was used to measure the levels of IFN-γ, TNF-α, IL-6, IL-10, IL-35, IL-4,IL-17, and TGF-β1 in the serum of AA mice after treatment (Figure 6A–H). As shown in Figure, compared to the normal group, the model group exhibited significantly elevated levels of IFN-γ, TNF-α, IL-17, and IL-6 (P < 0.01), while the levels of IL-10, TGF-β1, IL-4 and IL-35 were significantly decreased (P < 0.01). Following treatment, the levels of IFN-γ, TNF-α, and IL-6 in each treatment groups were significantly reduced compared to the model group (P < 0.05, P < 0.01), while the levels of TGF-β1, and IL-4 were significantly increased (P < 0.01). Furthermore, the levels of IL-10, IL-35 in the IST + GEG and IST + EPAG groups were significantly higher than in the model group (P < 0.01), while IL-17 was significantly lower than that in the model group (P < 0.01).These results indicate that IST + GEG, as well as IST + EPAG, are more effective in suppressing the secretion of inflammatory cytokines than the use of immunosuppressants alone. Figure 6Cytokine concentrations were assessed using ELISA in the serum of mice with AA. Results are shown as bar charts (A-H). Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01.Images A-H display cytokine levels (pg/mL) across conditions: N, M, IST, IST+EPAG, IST+GEG. Image A (IL-6): N ~3.5, M ~7.0, IST ~4.2, IST+EPAG ~3.3, IST+GEG ~3.6. Image B (IFN-gamma): N ~8.0, M ~11.0, IST ~9.0, IST+EPAG ~8.5, IST+GEG ~8.0. Image C (TNF-alpha): N ~19, M ~27, IST ~21, IST+EPAG ~20, IST+GEG ~20. Image D (IL-4): N ~20, M ~8, IST ~17, IST+EPAG ~18, IST+GEG ~20. Image E (TGF-beta1): N ~540, M ~170, IST ~350, IST+EPAG ~440, IST+GEG ~410. Image F (IL-10): N ~4.0, M ~2.7, IST ~3.3, IST+EPAG ~3.6, IST+GEG ~3.7. Image G (IL-35): N ~130, M ~90, IST ~100, IST+EPAG ~115, IST+GEG ~120. Image H (IL-17): N ~4, M ~15, IST ~13, IST+EPAG ~9, IST+GEG ~6.5. Significant differences marked by asterisks.A set of 8 bar charts showing serum cytokine concentrations across five mouse groups. Cytokine concentrations were assessed using ELISA in the serum of mice with AA. Results are shown as bar charts (A-H). Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01. GEG Can Promote the Proliferation and Differentiation of Tregs We detected changes in the proportion of naïve T cells, effector memory T cells (Tem), central memory T cells (Tcm), Tfh cells,and Tregs in the spleen of mice (Figure 7A–H). Compared with the normal group, the model group showed a significant decrease in naïve cells and Tregs (P < 0.01), a significant increase in Tem and Tfh cells (P < 0.01), and no significant change in Tcm. Compared with the model group, naïve, Tcm, and Treg cells were significantly increased in each treatment group (P < 0.05, P < 0.01), while Tem and Tfh cells were significantly decreased (P < 0.01).Furthermore, compared with the IST group, the IST + GEG and IST + EPAG treatment groups demonstrated a significantly higher proportion of Tregs (P < 0.05). The IST combined with GEG treatment group showed a reduction in Tfh cells and an increase in Tregs, strongly promoting the differentiation of naïve T cells into Tregs. Figure 7IST + GEG inhibited the proliferation and activation of effector memory T cells in AA mice, increasing the proportion of Tregs. (A) Percentage of Tregs in mouse spleen. (B) Representative flow cytometry plots showing the percentages of naïve T cells (Q1), Tcm (Q2), and Tem (Q4) in mice. (C) Percentage of Tfh cells in mouse spleen. (D-H) Quantitative analysis of cell populations presented as bar graphs. Data are expressed as mean ± SD, n = 3. *P < 0.05, **P < 0.01.A) Flow cytometry plots for Tregs: CD4 vs. side scatter, CD25 vs. Foxp3. Key percentages: N 16.33%, M 9.95%, IST 12.83%, IST+EPAG 17.74%, IST+GEG 16.89%. B) Plots for naïve, Tcm, Tem: CD4 vs. side scatter, CD44 vs. CD62L. Gate: 37.3%. N: Q1 66.4%, Q2 5.24%, Q3 19.3%, Q4 9.04%. M: Q1 34.8%, Q2 3.35%, Q3 38.8%, Q4 23.1%. IST: Q1 50.0%, Q2 8.96%, Q3 31.9%, Q4 9.06%. IST+EPAG: Q1 55.5%, Q2 9.02%, Q3 30.3%, Q4 5.20%. IST+GEG: Q1 56.6%, Q2 9.15%, Q3 26.5%, Q4 7.81%. C) Plots for Tfh: CD4 vs. side scatter, CD185 vs. CD287. Gate: P0 8.42%. Key percentages: N 10.14%, M 25.76%, IST 22.30%, IST+EPAG 18.28%, IST+GEG 19.07%. D) Treg bar chart: N 16%, M 9%, IST 12%, IST+EPAG 18%, IST+GEG 16%. E) Naive bar chart: N 65%, M 35%, IST 50%, IST+EPAG 55%, IST+GEG 56%. F) Tem bar chart: N 18%, M 38%, IST 31%, IST+EPAG 29%, IST+GEG 26%. G) Tcm bar chart: N 4.5%, M 4%, IST 9%, IST+EPAG 10%, IST+GEG 9%. H) Tfh bar chart: N 10%, M 26%, IST 22%, IST+EPAG 18%, IST+GEG 19%.Multi-panel flow cytometry and bar charts comparing Tregs, naïve, Tem, Tcm and Tfh across groups. IST + GEG inhibited the proliferation and activation of effector memory T cells in AA mice, increasing the proportion of Tregs. (A) Percentage of Tregs in mouse spleen. (B) Representative flow cytometry plots showing the percentages of naïve T cells (Q1), Tcm (Q2), and Tem (Q4) in mice. (C) Percentage of Tfh cells in mouse spleen. (D-H) Quantitative analysis of cell populations presented as bar graphs. Data are expressed as mean ± SD, n = 3. *P < 0.05, **P < 0.01. GEG Inhibited the Activation of FasL/Fas Apoptotic Pathway to Alleviate Treg Apoptosis We used Western blot analysis to determine the expression and activation of Fas, caspase-8, and caspase-7 proteins in CD4+ T lymphocyte suspensions derived from spleen tissue (Figure 8A and B), as well as the expression and activation of caspase3 proteins in Tregs (Figure 8C). Compared with the normal group, the protein expression of Fas and Caspase-7 significantly increased in the model group, while there was no significant difference in the protein expression of caspase8.The expression of cleaved caspase-8 and cleaved caspase-7 significantly increased (P < 0.05, P < 0.01). Compared with the model group, the IST + GEG group showed a significant decrease in Caspase-7 expression, and all treatment groups showed a significant decrease in Fas expression and cleaved caspase8,Cleaved Caspase-7 expression (P < 0.01). In Tregs derived from spleen tissue, we found that compared with the normal group, the expression of cleaved caspase3 in the model group was significantly increased (P < 0.01). Compared with the model group, the activation of IST + GEG cleaved caspase3 was significantly decreased (P < 0.01). These results suggest that GEG may inhibit Treg cell apoptosis in CD4+ T cells by regulating the activation of the Fas apoptotic signaling pathway. Figure 8IST + GEG inhibited the FasL/Fas mediated apoptosis pathway of Treg. (A) FasL/Fas expression status of T cells. (B) The expression of FasL/Fas apoptosis pathway related proteins in T cells. (C) The expression of FasL/Fas apoptosis pathway related proteins in Tregs. Results shown as a bar chart. GAPDH was used as an internal control. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01.The image A showing Fas-L and Fas. Fas-L bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: pg/mL, range 0 to 15. Values: N about 4, M about 9, IST about 6.5, IST+FAG about 3.5, IST+GEG about 3.0. Highest is M, lowest is IST+GEG. Western blot lanes: N, M, IST, IST+FAG, IST+GEG. Bands labeled Fas 55 kDa and GAPDH 37 kDa. Fas bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Relative expression (Fas/GAPDH), range 0 to 2.0. Values: N about 1.0, M about 1.5, IST about 1.0, IST+FAG about 0.6, IST+GEG about 0.7. Highest is M, lowest is IST+FAG. Asterisks mark significance. The image B showing caspase 8 and caspase-7. Western blot lanes: N, M, IST, IST+FAG, IST+GEG. Bands labeled Caspase 8 60 kDa, Cleaved Caspase 8 18 kDa, Caspase 7 35 kDa, Cleaved Caspase 7 20 kDa, GAPDH 37 kDa. Caspase 8 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Relative expression (Caspase 8/GAPDH), range 0 to 2.0. Values: N about 1.5, M about 1.45, IST about 1.45, IST+FAG about 1.45, IST+GEG about 1.5. Cleaved caspase 8 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Cleaved caspase 8/Caspase 8, range 0 to 0.8. Values: N about 0.5, M about 0.65, IST about 0.65, IST+FAG about 0.5, IST+GEG about 0.45. Highest is M and IST, lowest is IST+GEG. Caspase-7 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Relative expression (Caspase-7/GAPDH), range 0 to 2.0. Values: N about 0.7, M about 1.4, IST about 1.1, IST+FAG about 0.85, IST+GEG about 0.75. Highest is M, lowest is N. Cleaved caspase-7 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Cleaved caspase 7/Caspase 7, range 0 to 1.0. Values: N about 0.6, M about 0.9, IST about 0.6, IST+FAG about 0.7, IST+GEG about 0.7. Highest is M, lowest is N and IST. Asterisks mark significance. The image C showing caspase 3. Western blot lanes: N, M, IST, IST+FAG, IST+GEG. Bands labeled Caspase 3 35 kDa, Cleaved Caspase 3 17 kDa, GAPDH 37 kDa. Caspase 3 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Relative expression (Caspase 3/GAPDH), range 0 to 0.8. Values: N about 0.55, M about 0.55, IST about 0.70, IST+FAG about 0.68, IST+GEG about 0.58. Highest is IST, lowest is N and M. Cleaved caspase 3 bar chart. X-axis: N, M, IST, IST+FAG, IST+GEG. Y-axis: Cleaved caspase 3/Caspase 3, range 0 to 2.0. Values: N about 0.9, M about 1.4, IST about 1.0, IST+FAG about 1.0, IST+GEG about 1.0. Highest is M, lowest is N. Across A to C, the bar charts quantify the Western blot bands for Fas-L, Fas and downstream caspase proteins across the same five groups, with GAPDH as an internal control and asterisks indicating significant differences.A multi-part figure with bar charts and Western blots of Fas-L, Fas, caspase 8, caspase-7 and caspase 3. IST + GEG inhibited the FasL/Fas mediated apoptosis pathway of Treg. (A) FasL/Fas expression status of T cells. (B) The expression of FasL/Fas apoptosis pathway related proteins in T cells. (C) The expression of FasL/Fas apoptosis pathway related proteins in Tregs. Results shown as a bar chart. GAPDH was used as an internal control. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01. GEG Enhanced Treg Stability and Function in AA Mice via the miRNA-17/IKZF4 and miRNA-10a/BCL-6 Pathway We assessed the transcriptional levels of miRNA-17, miRNA-10a and mRNA-IKZF4, mRNA-HIF-1α, and mRNA-BCL6 in Tregs as shown in Figure 9A, as well as the corresponding protein expression levels (Figure 8B). Compared to the normal group, the model group exhibited significantly elevated transcriptional levels of miRNA-17, mRNA-HIF-1α and mRNA-BCL6 (P < 0.05, P < 0.01), while the transcriptional levels of mRNA-10a and mRNA-IKZF4 were significantly decreased (P < 0.01). In comparison to the model group, all treatment groups showed a significant reduction in miRNA-17 and mRNA-HIF-1α transcriptional levels (P < 0.05, P < 0.01), and a significant increase in mRNA-IKZF4 transcriptional levels (P < 0.05, P < 0.01), the transcription level of miRNA-10a in IST + EPAG and IST + GEG was significantly increased, and the transcription level of mRNA-BCL6 was reduced. Compared with the IST treatment group, the transcription levels of mRNA-IKZF4 in IST + GEG and IST + EPAG were significantly increased (P < 0.01). Furthermore, we measured the protein expression levels of HIF-1α, IKZF4, BCL-6, and Foxp3 in Tregs from the mice as shown in Figure 9B and C. In the model group, the protein expression of HIF-1α and BCL-6 was significantly elevated (P < 0.05, P < 0.01), whereas the protein expression of IKZF4 and Foxp3 was significantly decreased compared to the normal group (P < 0.05, P < 0.01). In contrast, treatment with IST, IST + EPAG, and IST + GEG significantly decreased HIF-1α protein expression and significantly increased the protein expression of Foxp3 compared to the model group. The protein expression of IKZF was significantly increased in the IST + EPAG and IST + GEG treatment groups (P < 0.05, P < 0.01), while the protein expression of BCL-6 was significantly reduced (P < 0.01). Compared with the IST group used alone, the IST + GEG and IST + EPAG groups can more effectively inhibit the transcription of miRNA-17, promote the transcription of its target gene mRNA-IKZF4 and related protein expression, promote the transcription of miRNA-10a, and inhibit the transcription and protein expression of its target gene mRNA-BCL6. Figure 9IST + GEG regulated microRNA and its target gene mRNA expression levels and protein expression levels. Primer design for RNA is shown in Table 1. (A) Transcription levels of microRNA and mRNA. Results shown as a bar chart. Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01. (B) WES (Western Electrophoresis System) automated protein blotting analysis to assess the expression of proteins. (C) Results shown as a bar chart. GAPDH was used as an internal control. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01.The image A showing four bar charts labeled microRNA-17, microRNA-10a, mRNA-HIF-1alpha, mRNA-IKZF4 and mRNA-BCL6. Each chart uses x-axis groups N, M, IST, IST plus EPAG, IST plus GEG. microRNA-17 y-axis label Relative microRNA expression, range 0 to 4. Bars: N about 1.0, M about 3.0, IST about 0.9, IST plus EPAG about 0.7, IST plus GEG about 0.7. microRNA-10a y-axis label Relative microRNA expression, range 0 to 2.0. Bars: N about 1.0, M about 0.4, IST about 0.7, IST plus EPAG about 0.9, IST plus GEG about 1.5. mRNA-HIF-1alpha y-axis label Relative mRNA expression, range 0 to 6. Bars: N about 1.0, M about 4.5, IST about 0.5, IST plus EPAG about 0.2, IST plus GEG about 0.2. mRNA-IKZF4 y-axis label Relative mRNA expression, range 0 to 2.5. Bars: N about 1.0, M about 0.1, IST about 0.4, IST plus EPAG about 1.7, IST plus GEG about 1.8. mRNA-BCL6 y-axis label Relative mRNA expression, range 0 to 3. Bars: N about 1.1, M about 2.3, IST about 2.2, IST plus EPAG about 1.7, IST plus GEG about 1.4. Significance brackets with asterisks appear above multiple group comparisons. The image B showing a protein blot with lanes N, M, IST, IST plus EPAG, IST plus GEG and rows HIF-1alpha 93 kilodalton, IKZF4 64 kilodalton, Foxp3 47 kilodalton, BCL6 79 kilodalton, GAPDH 37 kilodalton. The image C showing four bar charts with x-axis groups N, M, IST, IST plus EPAG, IST plus GEG. HIF-1alpha y-axis label Relative expression, range 0 to 4. Bars: N about 2.2, M about 3.2, IST about 2.5, IST plus EPAG about 2.1, IST plus GEG about 2.0. Foxp3 y-axis label Relative expression, range 0 to 1.5. Bars: N about 1.0, M about 0.5, IST about 0.8, IST plus EPAG about 0.95, IST plus GEG about 0.9. IKZF4 y-axis label Relative expression, range 0 to 1.5. Bars: N about 1.0, M about 0.6, IST about 0.7, IST plus EPAG about 0.8, IST plus GEG about 0.9. BCL6 y-axis label Relative expression, range 0 to 2.0. Bars: N about 0.8, M about 1.6, IST about 1.3, IST plus EPAG about 1.1, IST plus GEG about 1.0. Significance brackets with asterisks appear above multiple group comparisons.A multi-plot bar chart and protein blot image showing microRNA, mRNA and protein expression across groups. IST + GEG regulated microRNA and its target gene mRNA expression levels and protein expression levels. Primer design for RNA is shown in Table 1. (A) Transcription levels of microRNA and mRNA. Results shown as a bar chart. Data are presented as mean ± SD, n = 6, *P < 0.05, **P < 0.01. (B) WES (Western Electrophoresis System) automated protein blotting analysis to assess the expression of proteins. (C) Results shown as a bar chart. GAPDH was used as an internal control. Data are presented as mean ± SD, n = 3, *P < 0.05, **P < 0.01. Discussion This study elucidates the potential roles of miRNA-17, miRNA-10a, and miRNA-146a in the pathogenesis of AA through comprehensive bioinformatic analyses. Differential expression analysis based on the GEO database revealed that these three miRNAs were significantly dysregulated between AA patients and healthy controls, with miR-17 being upregulated and miR-10a and miR-146a being down-regulated. Subsequent GO and KEGG enrichment analyses indicated that these miRNAs may influence the pathological process of AA by modulating 12 functional pathways—including HIF-1, TNF and TGF-β signaling pathway—as well as 20 signaling pathways related to T cell differentiation in thymus, Cellular response to hypoxia, and Apoptotic signaling pathway. By cross-referencing multiple databases (miRDB, miRTarBase, miRWalk, and TargetScan), we identified 15 key target genes associated with AA that are potentially regulated by these miRNAs. Functional enrichment analysis of these target genes demonstrated significant associations with processes related to hematopoietic regulation and T cell differentiation, further supporting the crucial roles of these miRNAs in the immune dysfunction and hematopoietic failure characteristic of AA. Collectively, this study proposes a plausible molecular mechanism: Hypoxic stress within the bone marrow microenvironment triggers the dysregulation of miRNA regulatory networks. These miRNAs likely participate in the initiation and progression of AA by collectively regulating downstream target genes, thereby modulating T-cell function and differentiation, disrupting the stability of the hematopoietic microenvironment, and promoting the expression of apoptotic signals. These findings provide a theoretical foundation for future research into miRNA-based diagnostic biomarkers or therapeutic targets for AA. AA is primarily characterized by peripheral blood cell reduction, a decrease in BM hematopoietic cells, and fatty infiltration.31 In our model, BM cavities exhibited extensive adipocyte replacement and a profound reduction in nucleated cells. Flow cytometric analysis confirmed increased apoptosis of BMCs and a depletion of the hematopoietic stem cell (HSC) pool.Following intervention, both IST + GEG and IST + EPAG groups showed a significant reversal of these pathological features, characterized by reduced fatty infiltration and a restoration of HSC counts.Notably, IST + GEG and IST + EPAG treatments effectively improved the peripheral blood parameters of AA mice, with both treatments outperforming IST alone or IST + HDGEG in improving WBCs, RBCs, PLTs and HGB levels.The observed plateau or decline in efficacy with HDGEG suggests that excessive dosing may lead to metabolic saturation or signal interference. Experimental results indicate that GEG significantly potentiates the therapeutic efficacy of IST in alleviating immune-mediated BM injury, achieving a potency comparable to that of EPAG. As the master regulator of Tregs, impairment of Foxp3 function significantly compromises the immunosuppressive potency and lineage stability of the Tregs.32–34 Emerging evidence indicates that Treg stability is stringently regulated by the miR-17/IKZF4 signaling axis.35–37 IKZF4 serves as a critical co-factor for Foxp3-mediated transcriptional repression; its deficiency leads to the structural dysfunction of the Foxp3 transcriptional complex, resulting in a loss of suppressive activity. Within the pro-inflammatory microenvironment, pathologically elevated levels of HIF-1α and IL-6 induce the overexpression of miR-17, which subsequently inhibits IKZF4 mRNA transcription and protein translation.38,39 This study confirms that the IST + GEG combination effectively downregulates IL-6 levels, suppresses the accumulation of HIF-1α in CD4+ T cells, and reduces miR-17-5p transcriptional abundance. This intervention relieves the repression of IKZF4, thereby restoring IKZF4 protein levels within Tregs.These findings further corroborate our previous research demonstrating that GEG and Danggui Buxue Tang (DBT) modulate miR-17 transcription in AA murine models, which influences Eos expression within Tregs and enhances their stability.40 Furthermore, Treg stability and lineage commitment are regulated by the miR-10a-5p/Bcl-6 pathway. Under conditions where Bcl-6 (the lineage-determining transcription factor for Tfh) is highly expressed, Tregs are susceptible to phenotypic plastic shifts toward a Tfh-like profile.41 MiR-10a-5p targets the Bcl-6 transcript after transcription, thereby maintaining Treg phenotype stability and blocking Tfh conversion.41–43 Our experimental results demonstrate that IST + GEG significantly elevates miR-10a-5p transcriptional levels in CD4+ T cells, leading to the subsequent downregulation of Bcl-6 mRNA and protein expression. This mechanism effectively preserves Treg phenotypic stability and prevents aberrant differentiation into Tfh cells amidst AA-associated inflammation, ensuring the reconstruction of peripheral immune tolerance. In the inflammatory environment, activated effector T cells (primarily the Th1 subset) highly express Fas ligand (FasL).44 Correspondingly, Tregs express high levels of the Fas receptor (CD95), rendering them hypersensitive to FasL-mediated apoptosis.45 The engagement of FasL with Fas recruits the adapter protein Fas-associated protein with death domain (FADD), triggering a caspase cascade that ultimately culminates in Treg apoptosis.46,47 Western blot analysis revealed that IST + GEG significantly inhibits the apoptotic pathway initiated by the Fas/FasL signaling cascade, reducing systemic FasL levels and downregulating the expression of Fas, cleaved caspase-7/8 in CD4+ T cells, and cleaved caspase-3 specifically in Tregs. The reduction in FasL expression implies diminished activation of Fas receptors, both on Tregs and on effector T cells, thereby elucidating the mechanism underlying the generalized downregulation of apoptosis-related proteins in CD4⁺ T cells following treatment. In conclusion, the post-treatment recovery of Treg counts, the upregulation of Foxp3 expression, the reduction in Tfh proportions, and the increased levels of anti-inflammatory cytokines (IL-10 and IL-35) are the collective results of these synergistic signaling modulations. These findings indicate that IST + GEG effectively promotes Treg lineage stability by integrating differentiation control and apoptosis inhibition, ultimately reconstructing immune homeostasis in AA patients. During the pathological progression of AA, the secretion levels of core anti-inflammatory cytokines derived from Tregs, including IL-10, IL-35, and TGF-β1, are significantly diminished, thereby weakening their inhibitory potency against autoimmune responses.48 Specifically, the deficiency of TGF-β1 directly hinders the differentiation of naïve CD4⁺ T cells into induced Tregs (iTregs).49 Concurrently, under persistent antigenic stimulation, the naïve T cell pool undergoes attrition due to excessive differentiation toward effector and memory phenotypes. This results in the rapid activation of CD4⁺ Tem into effector T cells (Teff), which release a surge of pro-inflammatory cytokines (eg., IFN-γ and TNF-α), ultimately leading to immune-mediated destruction of HSCs.35,50–53 In this study, deep profiling via CyTOF-2 (mass cytometry) confirmed a profound imbalance in T-cell subsets within AA mice, while flow cytometric analysis corroborated the aberrant expansion of Teff cells alongside the contraction of both naïve T cell and Treg populations. Our experimental results demonstrate that the IST + GEG combination therapy significantly upregulates the secretion of inhibitory cytokines (IL-10, IL-35) and restores TGF-β1 levels. This therapeutic effect not only effectively suppresses the activation and proliferation of CD4⁺ Teff cells but also markedly curtails the release of pro-inflammatory IFN-γ and TNF-α. Consequently, this intervention restores T-cell homeostasis and alleviates immune-mediated BM destruction. According to Traditional Chinese Medicine theory, multi-component herbal formulations exert therapeutic effects through complex synergistic interactions.54,55 Our UPLC-MS/MS analysis identified 22 primary bioactive constituents in GEG.While several constituents of GEG, such as Ginsenoside Rb1, Baicalin, Vitamin C, and Rutin, have been individually identified to possess anti-apoptotic or immunomodulatory properties in various disease models,56–59 their collective synergistic impact within the unique hyper-inflammatory and hypoxic BM microenvironment of AA remains largely unexplored,which is a limitation of our current research. In the present study, GEO database mining identified differentially expressed microRNAs in AA patients that corroborate previous findings. Compared with previous studies by Liu et al60 and Takahashi et al23 our findings extend the miR-17/IKZF4 and miR-10a/Bcl-6 paradigms into the unique hypoxic and hyper-inflammatory BM niche of AA. We demonstrated that GEG effectively reverses the HIF-1α/IL-6/miR-17-mediated epigenetic repression of IKZF4 and restores miR-10a-5p to block the aberrant Treg-to-Tfh phenotypic shift. Specifically, GEG restores Treg lineage stability by modulating miRNA networks and inhibits the Fas/FasL signaling cascade to prevent the apoptotic depletion of Tregs. These combined effects collectively drive the remodeling of T-cell subset homeostasis and the restoration of cytokine balance.Unlike traditional single target therapies that focus on cell depletion or hematopoietic stimulation, GEG utilizes its 22 bioactive ingredients to help rebuild immune homeostasis through multi-target synergistic effects, and may ultimately help reduce the risk of recurrence during IST reduction. Conclusion GEG precisely modulates the miR-17-5p/IKZF4 and miR-10a-5p/Bcl-6 signaling axes within Tregs, thereby maintaining their lineage stability and preventing a phenotypic plastic shift toward Tfh-like cells.Furthermore, GEG effectively inhibits the Fas/FasL-mediated apoptotic cascade, preventing the excessive depletion of the Tregs. These synergistic effects collectively drive a comprehensive remodeling of T-cell subset homeostasis and restore cytokine balance.These findings provide an innovative, miRNA-targeted combinatorial strategy to enhance the efficacy of immunosuppressive therapy for AA.